title: Effects of azathioprine withdrawal in kidney recipients with stable function two years after transplant.
abstract: To assess the effects of azathioprine withdrawal, renal recipients with grafts > 2 yr function (103 study patients) were tapered off azathioprine over a 1-yr period and compared to 69 patients 2 yr after transplant who were not tapered (controls). Of the 103 study patients, 16 (15%) were living-donor transplants and 87 were cadaveric. Of the 69 control patients, 9 (13%) were living related transplants and 60 were cadaveric. The mean HLA match for those tapered was 3.3 Ag and 3.1 Ag for those remaining on azathioprine. Two study patients restarted azathioprine on their own. Age, sex, and cause of renal failure in both groups was similar. Of the 101 study patients remaining, 9 (8.8%) returned to dialysis due to biopsy proven chronic rejection. There were no acute rejection episodes. Six of the 69 control patients (8.7%) also returned to dialysis for the same reason. Of the 92 patients who have completed the taper, 85 have been off azathioprine for six or more months. There was not a significant difference between the mean 12- and 24-month creatinine levels of the study patients (1.6 mg%, 1.7 mg%) and those of the controls (1.5 mg%, 1.8 mg%). The mean 12- and 24-month hematocritis of patients tapered (41.3%, 40.8%) were comparable with patients not tapered (42.3%, 42.8%). Of interest, the mean hematocritis of both study and control patients rose from 28.9% and 33.5%, respectively, to 41.3% and 42.3% 1 yr following entry into the study. The mean 12- and 24-month white blood counts of those tapered (8.9, 8.7) did not differ significantly from those continued on azathioprine (8.8, 8.8). In stable renal transplant patients on triple drug immunosuppression for at least 2 yr, azathioprine can be discontinued, in a tapered protocol, without an increased risk of graft loss or compromise of renal function.
authors.affiliation: Department of Surgery, University of Tennessee Medical Center, Knoxville 37920, USA.
authors.forename: M H
authors.initials: MH
authors.lastname: Goldman
authors.forename: B
authors.initials: B
authors.lastname: Davis
authors.forename: E
authors.initials: E
authors.lastname: Cruz
authors.forename: P
authors.initials: P
authors.lastname: Miller
authors.forename: S L
authors.initials: SL
authors.lastname: Stevens
authors.forename: M B
authors.initials: MB
authors.lastname: Freeman
authors.forename: J D
authors.initials: JD
authors.lastname: Tyler
mesh_terms: D001379:Azathioprine / Q000627:therapeutic use*; D002908:Chronic Disease; D006084:Graft Rejection / Q000209:etiology*; D006400:Hematocrit; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D007958:Leukocyte Count; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D001379:Azathioprine